Erectile dysfunction: An overview

Human Reproduction Update

Volumn 3, Issue 5, 1997, Pages 455-466

  Fabbri, Andrea ^a   Aversa, Antonio ^a   Isidori, Aldo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Diagnosis; Erection; Nitric oxide; Therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CYCLIC AMP; DIHYDROERGOTOXINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCERYL TRINITRATE; GONADORELIN; NALTREXONE; NEUROPEPTIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYTOCIN; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA; VASOACTIVE AGENT; YOHIMBINE;

CLINICAL TRIAL; CORPUS CAVERNOSUM; DIAGNOSTIC APPROACH ROUTE; DRUG DELIVERY SYSTEM; DYSPEPSIA; HEADACHE; HOT FLUSH; HUMAN; HYPOGONADISM; IMPOTENCE; INJECTION PAIN; INTRACAVERNOUS DRUG ADMINISTRATION; INTRAURETHRAL DRUG ADMINISTRATION; MALE; MYALGIA; NERVE ENDING; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PENIS DISEASE; PENIS ERECTION; PENIS PROSTHESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROLACTINOMA; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; STIMULATION; TRANSDERMAL DRUG ADMINISTRATION; UNITED STATES; VASCULAR ENDOTHELIUM; VEIN OCCLUSION; VISUAL DISORDER;

HUMANS; IMPOTENCE; MALE; NITRIC OXIDE; PENILE ERECTION; VASODILATOR AGENTS;

EID: 0031419667     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/3.5.455     Document Type: Review

References (109)

1. Andersson, K.E. and Wagner, G. (1995) Physiology of penile erection. Physiol. Rev., 75, 191-236.
2. Argiolas, A. (1992) Oxytocin stimulation of penile erection. Pharmacology, site, and mechanism of action. Ann. N.Y. Acad. Sci., 652, 194-203.
3. Arletti, R., Benelli, A. and Bertolini, A. (1992) Oxytocin involvement in male and female sexual behavior. Ann. N.Y. Acad. Sci., 652, 180-193.
4. Arver, S., Dobs, A.S., Meikle, R.P. et al.. (1996) Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J. Urol., 155, 1604-1608.
5. 1 in non-organic male impotence: a new diagnostic approach. Int. J. Androl., 19, 307-313.
6. Aversa, A., Caprio, M., Inghilleri, M. et al.. (1996b) Erectile dysfunction in diabetic men. J. Endocrinol. Invest., 19 (Suppl. 5), 56.
7. thInt. Congr. Endocrinol., San Francisco, CA, 12-15 June, 1996, vol. 1, Abstr. 176, p. 178.
8. Ballard, S.A., Burslem, F.M.F, Gingell, C.J.C. et al.. (1996) In vitro profile of UK-92-480, an inhibitor of cyclic GMP-specific phosphodiesterase 5 for the treatment of male erectile dysfunction. J. Urol. 155 (Suppl.), 676A, Abstr. 1462.
9. Baskin, H.J. (1989) Endocrinologic evaluation of impotence. South. Med. J., 82, 446-451.
10. Bemelmans, B.L.H., Meuleman, E.J.H., Doesburg, W.H. et al.. (1994) Erectile dysfunction in diabetic men: the neurological factor revisited. J. Urol., 151, 884-889.
11. Bemelmans, B.L.H., Hendrikx, L.B.P.M., Koldewijn, E.L. et al.. (1995) Comparison of biothesiometry and neuro-urophysiological investigations for the clinical evaluation of patients with erectile dysfunction. J. Urol., 153, 1483-1486.
12. Benet, A.E. and Melman, A. (1995) The epidemiology of erectile dysfunction. Urol. Clin. North Am., 22, 699-709.
13. 1c receptors in drug induced penile erections in rats. Psychopharmacology, 101, 57-61.
14. Berger, R.E., Rothman, I. and Rigaud, G. (1993) Nonvascular causes of impotence. In Bennett, A.H. (ed.), Impotence - Diagnosis and Management of Erectile Dysfunction, W.B. Saunders Company, Philadelphia, pp. 106-123.
15. Beutler, L.E., Karacan, I., Anch, A.M. et al.. (1975) MMPI and MIT discriminators of biogenic and psychogenic impotence. J. Consult. Clin. Psychol., 43, 899-903.
16. Bogaert, F.A. (1997) Genital asymmetry in men. Hum. Reprod., 12, 68-72.
17. Boolell, M., Allen, M.J., Ballard, S.A. et al.. (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impotence Res., 8, 47-52.
18. Burnett, A.L., Lowenstein, C.J., Bredt, D. et al.. (1992) Nitric oxide: a physiologic mediator of penile erection. Science, 257, 401-403.
19. Carani, C., Granata, A.R.M., Faustini Fustini, M. and Marrama, P. (1996) Prolactin and testosterone: their role in male sexual function. Int. J. Androl., 19, 48-54.
20. Carter, C.S. (1992) Oxytocin and sexual behavior. Neurosci. Biobehav. Rev., 16, 131-144.
21. Christ, G.J. (1995) The penis as a vascular organ. Urol. Clin. North Am., 22, 727-745.
22. Christ, G.J., Richards, S. and Winkler, A. (1997) Integrative erectile biology: the role of signal transduction and cell-to-cell communication in coordinating corporal smooth muscle tone and penile erection Int. J. Impotence Res., 9, 69-84.
23. Cole, M. (1993) Psychological approaches to treatment. In Gregoire, A. and Pryor, J.P. (eds), Impotence: an Integrated Approach to Clinical Practice. Churchill Livingstone, New York, pp. 129-164.
24. Cormio, L., Nisen, H., Selvaggi, F.P. and Ruutu, M. (1996) Positive pharmacological erection test does not rule out arteriogenic erectile dysfunction. J. Urol., 156, 1628-1630.
25. Denil, J., Kupker, W., Al-Hasani, S. et al.. (1996) Successful combination of transrectal electroejaculation and intracytoplasmic sperm injection in the treatment of anejaculation. Hum. Reprod., 11, 1247-1249.
26. De Palma, R.G. (1997) Vascular surgery for impotence. Int. J. Impotence Res., 9, 61-67.
27. Derogatis, L.R. and Melisaratos, N. (1979) The DSFI: a multidimensional measure of sexual functioning. J. Sex. Marital Ther., 5, 244.
28. Dornan, W.A. and Malsbury, C.W. (1989) Neuropeptides and sexual behavior. Neurosci. Biobehav. Rev., 13, 1-15.
29. Drolet, G., Adams, M.A. and Heaton, J.P.W. (1996) Evidence for the central sites of action of apomorphine-induced erections. Int. J. Impotence Res., 8, 109, Abstr. A35.
30. Dufau, M.L., Tinajero, J.C. and Fabbri, A. (1993) Corticotropin-releasing factor: an antireproductive hormone of the testis. FASEB J., 7, 299-307.
31. Fabbri, A., Jannini, E.A., Ulisse, S. et al.. (1988) Low serum bioactive luteinizing hormone in non organic male impotence: possible relationship with altered gonadotropin-releasing hormone pulsatility. J. Clin. Endocrinol. Metab., 67, 867-875.
32. Fabbri, A., Jannini Gnessi, L. et al.. (1989a) Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology, 14, 103-111.
33. Fabbri, A., Jannini, E.A., Gnessi, L. et al.. (1989b) Neuroendocrine control of male reproductive function. The opioid system as a model of control at multiple sites. J. Steroid Biochem., 32, 145-150.
34. ca) channel in cultured human corporal smooth muscle cells. J. Urol., 153, 818-823.
35. Feldman, H.A., Goldstein, I., Hatzichristou, D.G. et al.. (1994) Impotence and its medical and psychological correlates: results of the Massachusetts male aging study. J. Urol., 151, 54-59.
36. Foreman, M.N. and Wenicke, J.F. (1990) Approaches for the development of oral drug therapies for erectile dysfunction. Semin. Urol., 8, 107-117.
37. Freeman, L.M. and Rissman, E.F. (1996) Neural aromatization and the control of sexual behavior. Trends Endocrinol. Metab., 7, 334-338.
38. Garban, H., Vernet, D., Freedman, A. et al.. (1995a) Effect of aging on nitric oxide-mediated penile erection in rats. Am. J. Physiol., 268, H467-H475.
39. Garban, H., Marquez, D., Cai, L. et al.. (1995b) Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. Biol. Reprod., 53, 1365-1372.
40. Garban, H., Moody, J., Marquez, D. et al.. (1996) Correction of erectile dysfunction by induction of iNOS in the penis. Int. J. Impotence Res., 8, 109, Abstr. A03.
41. Gentile, V., Modesti, A., La Fera, G. et al.. (1996) Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie's disease and veno-occlusive dysfunction. J. Androl., 2, 96-103.
42. Gessa, G.L., Paglietti, E. and Pellegrini-Quarantotti, B. (1979) Induction of copulatory behavior in sexually inactive rats by naloxone. Science, 204, 203-205.
43. Goldstein, J.A. (1986) Erectile function and naltrexone. Ann. Intern. Med., 105, 799-801.
44. Gomaa, A., Shalaby, M., Osman, M. et al.. (1996) Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide-dinitrate, and co-dergocrine mesylate. Br. Med. J., 312, 1512-1515.
45. Govier, F.E., McClure, R.D. and Kramer-Levien, D. (1996) Endocrine screening for sexual dysfunction using free testosterone determinations. J. Urol., 156, 405-408.
46. Gregoire, A. (1993) Questionnaires and rating scales. In Gregoire, A. and Pryor, J.P. (eds), Impotence: an Integrated Approach to Clinical Practice. Churchill Livingstone, New York, pp. 97-105.
47. Heaton, J.P.W., Adams, M.A., Morales, A. et al.. (1996) Apomorphine SL is effective in the treatment of non-organic erectile dysfunction: results of a multicenter trial. Int. J. Impotence Res., 8, 109, Abstr. A64.
48. Huang, P.L., Dawson, T.M., Bredt, T.S. et al.. (1993) Nitric oxide synthase gene. Cell, 75, 1273-1286.
49. Hultling, C., Rosenlund, B., Levi, R. et al.. (1997) Assisted ejaculation and in-vitro fertilization in the treatment of infertile spinal cord-injured men: the role of intracytoplasmic injection. Hum. Reprod., 12, 499-502.
50. Incrocci, L., Hop, W.C.J. and Slob, A.K. (1996) Visual erotic and vibrotactile stimulation and intracavernous injection in screening men with erectile dysfunction: a 3 year experience with 406 cases. Int. J. Impotence Res., 8, 227-232.
51. Insel, T.R., Young, L., Witt, D.M. and Crews, D. (1993) Gonadal steroids have paradoxical effects on brain oxytocin receptors. J. Neuroendocrinol., 5, 619-628.
52. Isidori, A., Di Luigi, L. and Conte, D. (1984) ACTH 1-17 effects and sexual behavior. Ric. Clin. Lab., 14, 247-249.
53. Kim, N., Vardi, Y., Padma-Nathan, H. et al.. (1993) Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J. Clin. Invest., 91, 437-442.
54. King, J.C. and Anthony, E.L.P. (1984) LH-RH neurons and their projection in humans and other mammals: species comparisons. Peptides, 5, 195-201.
55. Korenman, S.G. (1995) Advances in the understanding and management of erectile dysfunction. J. Clin. Endocrinol. Metab., 80, 1985-1988.
56. Levine, L.A. and Lenting, E.L. (1995) Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Urol. Clin. North Am., 22, 775-788.
57. Lue, T.F. (1994) Editorial: erectile dysfunction associated with cavernous and neurological disorders. J. Urol., 151, 890-891.
58. Lugg, J.A., Gonzales-Cadavid, N.F. and Rajfer, J. (1995a) The role of nitric oxide in erectile function. J. Androl., 16, 2-4.
59. Lugg, J.A., Rajfer, J. and Gonzales-Cadavid, N.F. (1995b) Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated erection in the rat. Endocrinology, 136, 1495-1501.
60. Magee, T., Fuentes, A.M., Garban, H. et al.. (1996) A novel penile neuronal nitric oxide synthase. Int. J. Impotence Res., 8, 109, Abstr. A01.
61. Mancini, M., Bartolini, M., Maggi, M. et al.. (1996) The presence of arterial anatomical variations can affect the results of duplex sonographic evaluation of penile vessels in impotent patients. J. Urol., 155, 1919-1923.
62. Marshall, G.A., Breza, J. and Lue, T.F. (1994) Improved hemodynamic response after long-term intracavernous injection for impotence. Urology, 43, 844-848.
63. Meinhardt, W., Kropman, R.F., Vermeij, P. et al.. (1997) The influence of medication on erectile function. Int. J. Impotence Res., 9, 17-26.
64. Melis, M.R., Mauri, A. and Argiolas, A. (1994) Apomorphine- and oxytocin-induced penile erection and yawning in intact and castrated male rats: effect of sexual steroids. Neuroendocrinology, 59, 349-354.
65. Merckx, L., Gerstenberg, T.C., Da Silva, J.P. et al.. (1996) A consensus on the normal characteristics of corpus cavernosum EMG. Int. J. Impotence Res., 8, 75-79.
66. Mills, T.M., Reilly, C.M. and Lewis, R.W. (1996) Androgens and penile erection: a review. J. Androl., 17, 633-638.
67. Moncada, S. (1992) The L-arginine:nitric-oxide pathway. Acta Physiol. Scand., 145, 201-227.
68. Montague, D.K., Barada, J.H., Belker, A.M. et al.. (1996) Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J. Urol., 156, 2007-2011.
69. Montorsi, F., Guazzoni, G., Barbieri, L. et al.. (1996) The effect of intracorporeal injection plus genital and audiovisual sexual stimulation versus second injection on penile color doppler ultrasonography parameters. J. Urol., 155, 536-540.
70. 1 in human corpus cavernosum smooth muscle. J. Urol., 153, 826-834.
71. Moreno, A.P., Campos de Carvalho, A.C., Christ, G.J. et al.. (1993) Gap junctional communications between corpus cavernosum smooth muscle cells in culture: gating behavior and single channel events. Am. J. Physiol., 264, C80-C85.
72. Mortimer, C.H., McNeilly, A.S., Fisher, R.A. et al.. (1974) Gonadotrophin-releasing hormone therapy in hypogonadal males with hypothalamic or pituitary dysfunction. Br. Med. J., 4, 617-621.
73. Murphy, M.R., Seckl, J.R., Burton, S. et al.. (1987) Changes in oxytocin and vasopressin secretion during sexual activity in men. J. Clin. Endocrinol Metab, 65, 738-741.
74. Nehra, A., Goldstein, I., Pabby, A. et al.. (1996) Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure J. Urol., 156, 1320-1329.
75. NIH Consensus Conference (1993) Impotence. J. Am. Med. Assoc., 270, 83-90.
76. Padma-Nathan, H., Hellstrom, W.J.G., Kaiser, F.E. et al.. for the MUSE study group (1997) Treatment of men with erectile dysfunction with transurethral alprostadil. N. Engl J. Med., 336, 1-7.
77. Palkovitz, M. (1987) Anatomy of neural pathways affecting CRH secretion. Ann. N.Y. Acad. Sci., 512, 139-148.
78. Pescatori, E., Hatzichristou, D.G., Namburi, S. and Goldstein, I. (1994) A positive intracavernous injection test implies a normal veno-occlusive but not necessarily normal arterial function: a haemodynamic study. J. Urol., 151, 1209-1216.
79. 1 in erectile failure: a survey of worldwide experience. J. Urol., 155, 802-815.
80. Porst, H., Derouet, H., Idzikowski, M. et al.. (1996) Oral phentolamine (Vasomax™) in erectile dysfunction - Results of a German multicenter study in 177 patients. Int. J. Impotence Res., 8, 109, Abstr. A72.
81. Quam, J.P., King, B.F., James, E.F. and Coll, P. (1989) Duplex and color Doppler sonographic evaluation of vasculogenic impotence. Am. J. Radiol., 153, 1141-1147.
82. Quigley, M.E., Sheehan, K.C., Casper, R.F. and Yen, S.S.C. (1980) Evidence for an increased opioid inhibition of LH secretion in hyperprolactinemic patients with pituitary microadenomas. J. Clin. Endocrinol. Metab., 50, 427-430.
83. Ra, S., Aoki, H., Fujioka, T. et al.. (1996) In vitro contraction of the canine corpus cavernosum penis by direct perfusion with prolactin and growth hormone. J. Urol., 156, 522-525.
84. Rajfer, J., Aronson, W.J., Bush, P.A. et al.. (1992) Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med., 326, 90-94.
85. Reilly, C.M., Zamorano, P., Stopper, V.S. and Mills, T.M. (1997) Androgenic regulation of NO availability in rat penile erection. J. Androl., 2, 110-115.
86. Reubi, J.C. and Mauret, R. (1985) Visualization of LH-RH receptors in the rat brain. Eur. J. Pharmacol, 106, 453-456.
87. Rabbins, A. (1996) Androgens and male sexual behavior - From mice to men. Trends Endocrinol. Metab., 7, 345-350.
88. Rust, J., Bennun, I., Crowe, M. and Golomboch, S. (1986) The Golomboch-Rust Inventory of Marital State (GRIMS). Sex. Marital Ther., 1, 55-60.
89. Saenz de Tejada, I., Goldstein, I. and Krane, R. (1988) Local control of penile erection. Urol. Clin. North Am., 15, 9-15.
90. Saenz de Tejada, I., Goldstein, I., Azadzoi, K. et al.. (1989) Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Engl. J. Med., 320, 1025-1030.
91. Saenz de Tejada, I., Carson, M.P., Goldstein, I. and Traish, A.M. (1991) Endothelin: localization, synthesis, activity and receptor types in human penile corpus cavernosum. Am. J. Physiol., 261, H1078-H1085.
92. Schiavi, R.C. and Rehman, J. (1995) Sexuality and aging. Uroi. Clin. North Am., 22, 711-726.
93. Seftel, A.D., Ganz, M.B., Saksa, B. et al.. (1996) eNOS in human penis. Int. J. Impotence Res., 8, 108, Abstr. A02.
94. Sidi, A.A., Cameron, J.S., Dykstra, D.D. et al.. (1987) Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury. J. Urol., 138, 539-545.
95. Sirinathsinghji, D.J.S. (1987) Inhibitory influence of corticotropin releasing factor on components of sexual behavior in the male rat. Brain Res., 407, 185-190.
96. Snyder, S.H. (1995) NO endothelial NO. Nature, 377, 196-197.
97. Spielberger, C.D., Gorsuch, R. and Lushene, R.E. (1970) Manual for the State Trait Anxiety Inventory. Consulting Psychologist Press, Palo Alto, CA.
98. Steers, W.D. (1990) Neural control of penile erection. Semin. Urol., 8, 66-79.
99. Stief, C.G., Eckel, H., Magert, H.J. et al.. (1996) cDNA sequence and expression of phosphodiesterase III in human cavernous tissue. Int. J. Impotence Res., 8, 109, Abstr. A19.
100. Susset, J.G., Lee, J. and Manbeck, K. (1996) Yohimbine in the office practice: a retrospective study. Int. J. Impotence Res., 8, 109, Abstr. A65.
101. Tamura, M., Kagawa, S., Kimura, K. et al.. (1995) Coexistence of nitric oxide synthase, tyrosine hydroxylase and vasoactive intestinal polypeptide in human penile tissue - a triple histochemical and immunohistochemical study. J. Urol., 153, 530-534.
102. Vanhatalo, S., Klinge, E., Sjostrand, N.O. and Soinila, S. (1996) NO synthesizing neurons originating at several different levels innervate rat penis. Neuroscience, 75, 891-899.
103. Virag, R. (1982) Intracavernous injection of papaverine for erectile failure. Letter to the Editor. Lancet, ii, 938.
104. Wagner, C.K. and Clemens, L.G. (1993) Neurophysin-containing pathway from the paraventricular nucleus of the hypothalamus to a sexually dimorphic motor nucleus in lumbar spinal cord. J. Comp. Neurol., 336, 106-116.
105. Wessells, H., Fusciarelli, K., Hansen, J. et al.. (1996) Melanotropic peptide for the treatment of psychogenic erectile dysfunction: double-blind crossover vehicle controlled study. Int. J. Impotence Res., 8, 109, Abstr. D102.
106. Yalla, S.V., Vickers, M.A., Sullivan, M.P. and Sarkarati, M. (1993) Sexual dysfunction and spinal cord injury. In Bennett, A.H. (ed.), Impotence - Diagnosis and Management of Erectile Dysfunction. W.B. Saunders Company, Philadelphia, pp. 175-185.
107. Yeh, K.H., Aoki, H., Matsuzaka, J. et al.. (1994) Participation of vasoactive intestinal polypeptide (VIP) as a humoral mediator in the erectile response of canine corpus cavernosum penis. J. Androl., 15, 187-193.
108. Zhao, W. and Christ, G.J. (1995) Endothelin-1 as a putative modulator of erectile dysfunction. II. Calcium mobilization in cultured human corporal smooth muscle cells. J. Urol., 154, 1571-1579.
109. Zung, W.W.K. (1970) Treatment prediction in depression using a self-rating scale. Biol. Psychiatry, 2, 321-329.